drugset / Trial / NCT04552704
CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study
Phase 1/2
Terminated
3 enrolled
Tianhong Li
National Cancer Institute (NCI) · collabOncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This phase I/II trial investigates the side effects and how well CD24Fc works in treating immune related adverse events in patients with solid tumors that have spread to other places in the body (advanced). CD24Fc may prevent autoimmune reactions due to the tissue damage induced by cancer treatment. CD24Fc binds to injured cell components and prevents inflammatory responses. CD24Fc also acts to turn off the immune system after it has been activated ("immune checkpoint"). Adding CD24Fc to standard treatment may shorten the recovery time and reduce the severity of side effects from immunotherapy.
Timeline
- Start
- 2020-10-30
- Primary completion
- 2021-02-03
- Completion
- 2022-01-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD24Fc | Protein / enzyme biologic | — | Intravenous |